| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5702658 | Urologic Oncology: Seminars and Original Investigations | 2017 | 7 Pages |
Abstract
GC adjuvant chemotherapy is a safe conservative treatment for T1G3 bladder cancer, but effective is really a phase II study. Patients with T1G3 bladder cancer with concomitant CIS should be treated more aggressively because of the high risk of progression.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Guo-liang M.D., Lian-hua M.D., Qiang M.D., Zhao-liang M.D., Xue-hui M.D., Yi-ran M.D., Juan-jie M.D.,